Boehringer Ingelheim and Eli Lilly and Company have announced the availability of My Well Planner, a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health. My Well Planner is designed to address the emotional barriers people with type 2 diabetes face every day. Read more
Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, announced the start of the first Phase I clinical study of ZP2929.
ZP2929 is a dual acting glucagon/GLP-1 peptide agonists, invented by Zealand Pharma and with global rights out-licensed to Boehringer Ingelheim as part of a global license and research … Read more
The European Commission has given Marketing Authorization to Jentadueto (linagliptin/metformin hydrochloride) tablets,Boehringer Ingelheim and Eli Lilly’s medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta tablets, marketed under the trade name Trajenta in Europe) and metformin in a single tablet taken twice daily. Read more
Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim’s investigational novel basal insulin analog, LY2605541, show that that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than Lantus (insulin glargine) in patients… Read more
Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1c) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks… Read more
Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin, marketed under the name Tradjenta in the U.S, at the American Diabetes Association’s (ADA) 72nd Scientific Sessions. The new studies… Read more
The European Medicines Agency’s (EMA) medicinal committee has recommended the approval of Jentadueto, a type 2 diabetes drug, from Boehringer Ingelheim and Eli Lilly. Jentadueto (linagliptin/metformin hydrochloride) tablets are a medicine combining the DPP-4 inhibitor, linagliptin… Read more
Boehringer Ingelheim and Eli Lilly announced results of a Phase 3 study in African American adults that shows taking Tradjenta (linagliptin) 5mg once-daily tablets sgnificantly reduces hemoglobin A1c (HbA1c)… Read more
Eli Lilly and Boehringer Ingelheim have announced Jentadueto tablets are now available by prescription in pharmacies across the U.S. Jentadueto is a new prescription medication for type 2 diabetes patients who need to control their blood sugar. Jentadueto is a twice… Read more
The FDA has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet… Read more
